The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 701–800 of 999
Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1
Sin, Y., Yoshimatsu, Y., Noguchi, R., Tsuchiya, R., Sei, A., Ono, T., Toki, S., Kobayashi, E., Arakawa, A., Sugiyama, M., et al. (2020) · Human Cell · doi:10.1007/s13577-020-00403-0 · Cited by 8
Tran, V. P., Kim, R., Maertens, M., Härtung, T., & Maertens, A. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.674370 · Cited by 8
Vredevoogd, D. W., Apriamashvili, G., & Peeper, D. S. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100043 · Cited by 7
Zhao, B., Rao, Y., Leighow, S. M., O’Brien, E. P., Gilbert, L. A., & Pritchard, J. R. (2022) · Nature Communications · doi:10.1038/s41467-022-28045-w · Cited by 8
Self-citationExploiting gene dependency to inform drug development for multiple myeloma
Went, M., Hoang, P. H., Law, P., Kaiser, M., & Houlston, R. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-16940-7 · Cited by 8
Abe, T., Horisawa, Y., Kikuchi, O., Ozawa‐Umeta, H., Kishimoto, A., Katsuura, Y., Imaizumi, A., Hashimoto, T., Shirakawa, K., Takaori‐Kondo, A., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175321 · Cited by 8
Self-citationVoutsadakis, I. A. (2022) · Medicina · doi:10.3390/medicina58101498 · Cited by 8
Maeda, Y., Koshizaka, M., Shoji, M., Kaneko, H., Kato, H., Maezawa, Y., Kawashima, J., Yoshinaga, K., Ishikawa, M., Sekiguchi, A., et al. (2023) · Aging · doi:10.18632/aging.204681 · Cited by 8
Spendlove, M., Gibson, T. M., McCain, S., Stone, B. C., Gill, T., & Pickett, B. E. (2023) · PeerJ · doi:10.7717/peerj.16088 · Cited by 9
Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis
Li, Z., Fong, W. P., Zhang, D., Luo, H., Chen, D., Cai, Y., Chen, Z., Duan, J.-L., Huang, Z.-Y., Lu, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00598-7 · Cited by 8
CRISPRi screen of long non-coding RNAs identifies LINC03045 regulating glioblastoma invasion
Tsung, K., Liu, K., Han, J. S., Deshpande, K., Doan, T. T. N., Loh, Y. E., Ding, L., Yang, W., Neman, J., Dou, Y., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011314 · Cited by 9
Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers
Kabeer, F., Tran, H., Andronescu, M., Singh, G., Lee, H., Salehi, S., Wang, B., Biele, J., Brimhall, J., Gee, D., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03318-3 · Cited by 9
Gong, X., Liu, C., Tang, H., Wu, S., & Yang, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1460412 · Cited by 9
Zhao, Z., & Bourne, P. E. (2020) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b01134 · Cited by 8
Barkovskaya, A., Goodwin, C. M., Seip, K., Hilmarsdóttir, B., Pettersen, S., Stalnecker, C. A., Engebraaten, O., Briem, E., Der, C. J., Moestue, S. A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12951 · Cited by 8
AutoOmics: New multimodal approach for multi-omics research
Xu, C., Liu, D., Zhang, L., Xu, Z., He, W., Jiang, H., Zheng, M., & Qiao, N. (2021) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2021.100012 · Cited by 8
A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
Grant, E. K., Fallon, D. J., Hann, M. M., Fantom, K. G. M., Quinn, C. J., Zappacosta, F., Annan, R. S., Chung, C., Bamborough, P., Dixon, D. P., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202008361 · Cited by 8
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers
Voutsadakis, I. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01695-y · Cited by 8
Identifying Lethal Dependencies with HUGE Predictive Power
Gimeno, M., José‐Eneriz, E. S., Rubio, A., Gárate, L., Miranda, E., Castilla, C., Agirre, X., Prósper, F., & Carazo, F. (2022) · Cancers · doi:10.3390/cancers14133251 · Cited by 8
Liu, L., Rovers, E., & Schapira, M. (2022) · Database · doi:10.1093/database/baac088 · Cited by 8
Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks
Qin, S., Wan, L., Yu, H., Xu, M., Li, C., Fu, L., Sun, S., He, Y., Lv, J., He, W., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032244 · Cited by 8
Genome‐wide screen for anticancer drug resistance in haploid human embryonic stem cells
Segal, E., Nissenbaum, J., Peretz, M., Golan‐Lev, T., Cashman, R., Philip, H., Reubinoff, B. E., Kopper, O., & Benvenisty, N. (2023) · Cell Proliferation · doi:10.1111/cpr.13475 · Cited by 7
CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma
Wenger, A., Karlsson, I., Kling, T., & Carén, H. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01498-6 · Cited by 9
CRISPR in medicine: applications and challenges
Sun, J., Hu, H., Cheng, Y., & Lu, X. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaa011 · Cited by 10
DGK and DZHK position paper on genome editing: basic science applications and future perspective
Brandes, R. P., Dueck, A., Engelhardt, S. H., Kaulich, M., Kupatt, C., Angelis, M. T. D., Leisegang, M. S., le Noble, F. A. C., Moretti, A., Müller, O. J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-020-00839-3 · Cited by 8
Anvar, N. E., Lin, C., Ma, X., Wilson, L., Steger, R., Sangree, A. K., Colic, M., Wang, S. H., Doench, J. G., & Hart, T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522655 · Cited by 8
He, Y., Xue, Y., Wang, J., Huang, Y., Liu, L., Huang, Y., & Gao, Y. Q. (2023) · Genome Research · doi:10.1101/gr.277737.123 · Cited by 8
Sadagopan, A., Garaffo, N., Chang, H.-J., Schreiber, S. L., Meyerson, M. M., & Gibson, W. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.27.605429 · Cited by 8
Zhang, H., Read, A., Cataisson, C., Yang, H. H., Lee, W., Turk, B. E., Yuspa, S. H., & Luo, J. (2024) · Science Signaling · doi:10.1126/scisignal.add5073 · Cited by 8
Data Commoning in the Life Sciences
Priego, L. P., & Wareham, J. D. (2024) · MIS Quarterly · doi:10.25300/misq/2023/17439 · Cited by 13
Yu, S., Si, Y., Yu, J., Jiang, C., Cheng, F., Xu, M., Fan, Z., Liu, F., Liu, C., Wang, Y., et al. (2024) · Cancer Science · doi:10.1111/cas.16356 · Cited by 8
CRISPR /Cas Technology in Disease Prevention and Control of Aquatic Animals
Lin, N., Zhang, J., Wang, Y., & Zhang, Z. (2024) · Reviews in Aquaculture · doi:10.1111/raq.12995 · Cited by 7
Multidimensional analyses identify genes of high priority for pancreatic cancer research
Nwosu, Z. C., Giza, H. M., Nassif, M., Charlestin, V., Menjivar, R. E., Kim, D.-H., Kemp, S. B., Sajjakulnukit, P., Andren, A. C., Zhang, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174264 · Cited by 9
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope
Wu, Y., Wang, Y., Wang, Y., Qiu, H., Yuan, X., Xiong, H., & Zou, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189370 · Cited by 8
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches
Ribeiro, A., Fote, G., Himstead, A. S., Zheng, M., Elliott, E., Smith, S. M., Lou, J. J., & Yuen, C. (2025) · Biomedicines · doi:10.3390/biomedicines13081963 · Cited by 7
Billmann, M., Costanzo, M., Zhang, X., Hassan, A. Z., Rahman, M., Brown, K. R., Chan, K. S., Tong, A. H. Y., Pons, C., Ward, H. N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.044 · Cited by 17
Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting
Wang, Z., Tang, M., & Konopleva, M. (2026) · Oncogenesis · doi:10.1038/s41389-026-00632-2 · Cited by 10
A compendium of next-generation patient-derived models for diverse cancers
ElHarouni, D., Al‐Jazrawe, M., Choi, S., Dede, M., Hinoue, T., Misek, S. A., Noh, H., Zanella, L., Tseng, Y.-Y., Francies, H. E., et al. (2026) · Nature · doi:10.1038/s41586-026-10806-y · Cited by 9
Mou, J., Huang, M., Wang, F., Xu, X., Xie, H., Lu, H., Li, M., Li, Y., Kong, W., Chen, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0241 · Cited by 6
Enigmatic role of WRN-RECQL helicase in DNA repair and its implications in cancer
Gupta, P., Majumdar, A. G., & Patro, B. S. (2022) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.60 · Cited by 7
Wang, B., Xu, Y., Wan, A. H., Wan, G., & Wang, Q. (2024) · Nature Protocols · doi:10.1038/s41596-024-00995-z · Cited by 7
Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
Schneider, C., Spaink, H., Alexe, G., Dharia, N. V., Meyer, A., Merickel, L. A., Khalid, D., Scheich, S., Häupl, B., Staudt, L. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3560 · Cited by 7
WRN Helicase: Is There More to MSI-H than Immunotherapy?
Wainberg, Z. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0771 · Cited by 7
Yousefi, M., See, W. R., Aw‐Yong, K. L., Lee, W. S., Yong, C. L., Fanusi, F., Smith, G. J. D., Ooi, E. E., Li, S., Ghosh, S., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae452 · Cited by 7
Li, L., Feng, C., Zhang, W., Qi, L., Liu, B., Wang, H., Li, C., Li, Z., Tu, C., & Zhou, W. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10171 · Cited by 7
A Flexible, Pooled CRISPR Library for Drug Development Screens
Blanck, M., Budnik-Zawilska, M., Lenger, S. R., McGonigle, J. E., Martin, G. R. A., le Sage, C., Lawo, S., Pemberton, H. N., Tiwana, G. S., Sorrell, D. A., et al. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0066 · Cited by 7
Fragment-Based Discovery of AF9 YEATS Domain Inhibitors
Liu, Y., Jin, R., Lu, H., Bian, K., Wang, R., Wang, L., Gao, R., Zhang, J., Wu, J., Yao, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073893 · Cited by 7
Morales, J., Allegakoen, D., García, J. A., Kwong, K., Sahu, P., Fajardo, D. A., Pan, Y., Horlbeck, M., Weissman, J., Gustafson, W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.162207 · Cited by 6
Exploring the DNA damage response pathway for synthetic lethality
Xu, X., Nowsheen, S., & Deng, M. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00087-w · Cited by 8
The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms
Mahumud, R. A., & Shahjalal, M. (2022) · Cancers · doi:10.3390/cancers14246202 · Cited by 8
Talbot, T., Lu, H., & Aboagye, E. O. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00589-z · Cited by 7
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Sharma, S., & Wright, G. J. (2020) · Journal of Visualized Experiments · doi:10.3791/60803 · Cited by 7
Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics
George, B., Pillai, P. M., Paul, A. M., Revikumar, A., Leitzel, K. E., Ali, S. M., Sandiford, O. A., Lipton, A., Rameshwar, P., Hortobágyi, G. N., et al. (2021) · Cells · doi:10.3390/cells10020433 · Cited by 7
Recent Progress of Photocage Molecules and Materials
Wei, T., Jiang, L., Chen, Y., & Chen, X. (2021) · 化学学报 · doi:10.6023/a20080361 · Cited by 7
Illuminating lncRNA Function Through Target Prediction
Chiu, H., Somvanshi, S., Chen, T.-W., & Sumazin, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1697-0_22 · Cited by 7
Wang, Y., Lin, C., Yao, C., Hsu, C., Tsai, C., Hou, H., Chou, W., & Tien, H. (2021) · British Journal of Haematology · doi:10.1111/bjh.17837 · Cited by 7
Zhang, Y., & Erb, M. A. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100011 · Cited by 7
Marques, A.-S. M. C., Bauer, L. G., Nguyen, T. A., Orta, A. G., Venne, J. L., Cheng, L., Balıkçı, E., Tivon, B., London, N., Kubicek, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.16.643557 · Cited by 7
Medea: An AI agent for therapeutic reasoning across biological contextsPreprint
Sui, P., Li, M. M., Munson, B. P., Gao, S., Shen, W., Giunchiglia, V., Shen, A. N., Huang, Y., Kong, Z., Licon, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.16.696667 · Cited by 13
Beltrán‐Navarro, Y. M., Reyes‐Cruz, G., & Vázquez‐Prado, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.922025 · Cited by 6
Muñoz-Ayala, A., Chimal‐Vega, B., & García‐González, V. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.05.011 · Cited by 6
Rath, S., Panda, S., Sacchettini, J. C., & Berthel, S. J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00034 · Cited by 6
Liu, M., Zhao, Z., Wang, C., Sang, S., Cui, Y., Lv, C., Yang, X., Zhang, N., Xiong, K., Chen, B., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216991 · Cited by 6
Chemical coverage of human biological pathways
Kwak, H. A., Liu, L., Tredup, C., Röhm, S., Prinos, P., Böttcher, J., & Schapira, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104144 · Cited by 6
Maintenance of p-eIF2α levels by the eIF2B complex is vital for colorectal cancer
Škapik, I. P., Giacomelli, C., Hahn, S., Deinlein, H., Gallant, P., Diebold, M., Biayna, J., Hendricks, A., Olimski, L., Otto, C., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00381-9 · Cited by 6
High-dimensional signalling analysis of organoids
Dobric, A., & Tape, C. J. (2025) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2025.102488 · Cited by 7
GPX4-dependent ferroptosis sensitivity is a fitness trade-off for cell enlargement
Chan, K. Y., Yu, Y., Kong, Y., Cheng, L., Yao, R., Chair, P. S. Y., Wang, P., Wang, R., Sun, W., He, R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112363 · Cited by 7
Rapid and robust validation of pooled CRISPR knockout screens using CelFi
Loughran, A. J., Narina, S., Klein, J. D., Siwak, J. F., Connelly, J. P., & Pruett‐Miller, S. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96095-3 · Cited by 7
Fang, J., Fang, J., Singh, S., Wells, B., Wu, Q., Jin, H., Janke, L., Wan, S., Steele, J. A., Connelly, J. P., et al. (2025) · eLife · doi:10.7554/elife.101299.3 · Cited by 9
Guo, L., Duan, X., Li, J., Hao, Z., Bi, Y., Chen, Y., Du, X., & Wu, S. (2025) · Journal of Virology · doi:10.1128/jvi.00320-25 · Cited by 6
Proteomic compensation by paralogs preserves protein interaction networks after gene loss in cancer
Venkatesh, A., Quinn, N., Upadhya, S. R., Kegel, B. D., Bolado‐Carrancio, A., Lefeivre, T., Dennler, O., Wynne, K. J., von Kriegsheim, A., & Ryan, C. J. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00122-4 · Cited by 10
Abdelrazik, N. M., Patel, A., Conn, A., Sutton, C. W., Kantamneni, S., & Shnyder, S. D. (2025) · Cells · doi:10.3390/cells14120929 · Cited by 6
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition.
Lueg, G. A., Zhang, J., Faronato, M., Gorelik, A., Kallemeijn, W. W., Falciani, F., Walton, J., Houghton, J. W., Vannini, S., Poon, E., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116180 · Cited by 7
Strategies for the drug development of cancer therapeutics
Liu, H., Ma, Y., Chen, W., Gu, X., Sun, J., & Li, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656012 · Cited by 7
Glossop, P. A., Brear, P., Wright, S., Flanagan, N. J., Glossop, M. S., Lane, C. A. L., Butt, R. P., Spring, D. R., Hyvönen, M., & Cawkill, D. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01807 · Cited by 6
Targeting DNA Damage Repair Pathways Beyond PARP Inhibition
Merry, E., & Gourley, C. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01183-z · Cited by 8
c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
Min, W., He, C., Zhang, S., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602900 · Cited by 6
Mendik, P., Kerestély, M., Kamp, S., Deritei, D., Kunšič, N., Vassy, Z., Csermely, P., & Veres, D. V. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00228-7 · Cited by 6
Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity
Sankaran, D., Revikumar, A., Paul, A. M., George, B., Kala, R., Saini, S., & Kumar, R. (2023) · Biomedicines · doi:10.3390/biomedicines11020462 · Cited by 6
Gui, C., Wei, J., Mo, C., Liang, Y., Cen, J., Chen, Y., Wang, D., & Luo, J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85209 · Cited by 6
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens
Lee, T. W., Hunter, F. W., Tsai, P., Print, C. G., Wilson, W. R., & Jamieson, S. M. F. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00664-5 · Cited by 8
Collateral lethality: A unique type of synthetic lethality in cancers
Zhao, Z., Zhu, L., Luo, Y., Xu, H., & Zhang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108755 · Cited by 6
Merk, D. J., Tsiami, F., Hirsch, S., Walter, B., Haeusser, L. A., Maile, J. D., Stahl, A., Jarboui, M. A., Lechado‐Terradas, A., Klose, F., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03438-w · Cited by 6
Open Targets: 10 years of partnership in target discovery
Hulcoop, D. G., Trynka, G., & McDonagh, E. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/d41573-024-00204-2 · Cited by 6
Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells
Santiappillai, N. T., Cao, Y., Hakeem-Sanni, M. F., Yang, J. Y. H., Quek, L., & Hoy, A. J. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00099-0 · Cited by 6
Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery
Scott, F., Fala, A. M., Takarada, J. E., Ficu, M. P., Pennicott, L. E., Reuillon, T. D., Couñago, R. M., Massirer, K. B., Elkins, J. M., & Ward, S. E. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128588 · Cited by 6
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Sharma, S., & Wright, G. J. (2020) · Journal of Visualized Experiments · doi:10.3791/60803-v · Cited by 6
Zhao, W., Pei, Q., Zhu, Y., Zhan, D., Mao, G., Wang, M., Qiu, Y., Zuo, K., Pei, H., Sun, L., et al. (2022) · Cancers · doi:10.3390/cancers14225607 · Cited by 6
A review on bioinformatics advances in CRISPR-Cas technology
Sharma, S., Murmu, S., Das, R., Tilgam, J., Saakre, M., & Paul, K. (2022) · Journal of Plant Biochemistry and Biotechnology · doi:10.1007/s13562-022-00811-3 · Cited by 6
An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
Altintas, D. M., Cerqua, M., Laurentiis, A. D., Trusolino, L., Boccaccio, C., & Comoglio, P. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-28648-3 · Cited by 7
Self-citationWRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI)
Chan, E. M., Foster, K. J., & Bass, A. J. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_17 · Cited by 6
Issa, I. I., Due, H., Brøndum, R. F., Veeravakaran, V., Haraldsdóttir, H., Sylvester, C., Brogaard, A., Dhanjal, S., Schmierer, B., & Dybkær, K. (2024) · Cancers · doi:10.3390/cancers16132437 · Cited by 6
Computational Methods for Analysis of Large-Scale CRISPR Screens
Lin, X., Chemparathy, A., Russa, M. F. L., Daley, T., & Qi, L. S. (2020) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020520-113523 · Cited by 7
Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targets
de Falco, A., Dezső, Z., Ceccarelli, F., Cerulo, L., Ciaramella, A., & Ceccarelli, M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa968 · Cited by 6
Tools for Decoding Ubiquitin Signaling in DNA Repair
Foster, B., Attwood, M., & Gibbs‐Seymour, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760226 · Cited by 5
Park, T. Y., Leiserson, M. D. M., Klau, G. W., & Raphael, B. J. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100099 · Cited by 8
Wilson, J., & Loizou, J. I. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13272 · Cited by 6
Reduced gene templates for supervised analysis of scale-limited CRISPR-Cas9 fitness screens
Vinceti, A., Perron, U., Trastulla, L., & Iorio, F. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111145 · Cited by 6
Self-citationZhang, Y., Liang, D.-M., & Du, P.-F. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad097 · Cited by 6
Effectively utilizing publicly available databases for cancer target evaluation
Croft, D. R., Lodhia, P., Lourenco, S. D. S., & MacKay, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad035 · Cited by 7
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
